Exscientia
Exscientia is a UK-based company that leverages AI to enhance the drug discovery process, notably reducing design time for candidate molecules and achieving the milestone of developing the first AI-designed molecules to enter clinical trials.
Company Services
Exscientia utilizes artificial intelligence to accelerate the drug discovery process. Their approach reduces the time required to design candidate molecules to less than a year. The company employs a patient-first AI platform that has demonstrated improved treatment outcomes in a prospective interventional study. By combining AI with rigorous experimental validation, Exscientia ensures the development of promising drug discovery assets.
AI-Designed Molecules and Clinical Trials
Exscientia has developed the first AI-designed molecules that have successfully entered clinical trials. This achievement demonstrates the effectiveness of their AI technology in creating viable drug candidates. By optimizing drug properties simultaneously, Exscientia enhances the discovery of therapeutically beneficial candidates, moving them from design to clinical testing stages efficiently.
Headquarters and Laboratory Facilities
Exscientia's headquarters is located in the Schrödinger Building at Oxford Science Park, Oxford, UK. The company conducts precision experiments within over 47,000 square feet of laboratory space. These facilities are equipped with advanced technologies, including Surface Plasmon Resonance and X-ray crystallography, which support their rigorous experimental validation processes.
Precision Medicine Approach
Focusing on precision medicine, Exscientia uses patient tissue data to enhance drug discovery and improve health outcomes. Their AI platform not only designs molecules but also interprets data from these tissues, tailoring treatments to individual patient characteristics. This approach ensures that newly developed drugs are more effective and have higher success rates in clinical applications.
